• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.

    2/17/26 9:22:12 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $DFTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Definium Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    24477V105

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    24477V105


    1Names of Reporting Persons

    DRIEHAUS CAPITAL MANAGEMENT LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,537,202.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,537,202.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,537,202.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.64 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  The issuer changed its name from Mind Medicine (MindMed), Inc. to Definium Therapeutics, Inc. on January 12, 2026.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Definium Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    One World Trade Center, Suite 8500, New York, New York, 10007
    Item 2. 
    (a)Name of person filing:

    Driehaus Capital Management LLC
    (b)Address or principal business office or, if none, residence:

    25 East Erie Street, Chicago, Illinois 60611
    (c)Citizenship:

    USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    24477V105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6537202
    (b)Percent of class:

    6.64  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    6537202

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    6537202

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The shares reported by Driehaus Capital Management LLC (DCM) are held by numerous clients on a fully discretionary basis in accounts managed by DCM. Securities held in these clients' accounts are included in this report to reflect that DCM may have voting power and has dispositive power. To the best of DCM's knowledge, none of the referenced clients have the right to receive dividends or direct proceeds from the sale of interests relating to more than 5% of the class.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    DRIEHAUS CAPITAL MANAGEMENT LLC
     
    Signature:Janet McWilliams
    Name/Title:Janet McWilliams/General Counsel
    Date:02/17/2026
    Get the next $DFTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DFTX

    DatePrice TargetRatingAnalyst
    2/24/2026$25.00Outperform
    Wolfe Research
    1/30/2026$30.00Buy
    Jefferies
    More analyst ratings

    $DFTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Definium Therapeutics Announces New Employee Inducement Grants

    Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of (i) options to purchase an aggregate of 134,540 common shares of the Company (the "Options") and (ii) 34,500 performance share units (the "PSUs") (assuming achievement at target levels of performance) that, if earned, will be settled in Definium common shares upon vesting, with effective grant dates of February 24, 2026, February 27, 2026 and March 9, 2026.

    3/9/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

    Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate1. The Drug Enforcement Administration raised its 2026 production quotas for controlled research compounds by 67%, reflecting expanding clinical trial activity across the therapeutics landscape2. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), a

    3/9/26 10:50:00 AM ET
    $ATAI
    $CMPS
    $DFTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

    Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).

    2/27/26 11:44:00 AM ET
    $ATAI
    $DFTX
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $DFTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Wiley Matthew T. was granted 115,000 shares (SEC Form 4)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    2/5/26 5:00:10 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Roberts Brandi was granted 150,000 shares (SEC Form 4)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    2/5/26 4:57:19 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Legal Officer Sullivan Mark was granted 125,000 shares, increasing direct ownership by 44% to 407,576 units (SEC Form 4)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    2/5/26 4:55:45 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    SEC Filings

    View All

    SEC Form 10-K filed by Definium Therapeutics Inc.

    10-K - Definium Therapeutics, Inc. (0001813814) (Filer)

    2/26/26 4:16:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Definium Therapeutics, Inc. (0001813814) (Filer)

    2/26/26 4:10:27 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.

    SCHEDULE 13G - Definium Therapeutics, Inc. (0001813814) (Subject)

    2/17/26 9:22:12 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Definium Therapeutics with a new price target

    Wolfe Research initiated coverage of Definium Therapeutics with a rating of Outperform and set a new price target of $25.00

    2/24/26 7:52:18 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies initiated coverage on Definium Therapeutics with a new price target

    Jefferies initiated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $30.00

    1/30/26 6:43:41 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Leadership Updates

    Live Leadership Updates

    View All

    Definium Therapeutics Appoints Roger Adsett to Board of Directors

    Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium's next phase of growth Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. "We are thrilled to welcome Roger to our Board of Directors," said Rob Barrow, Chief Executive Officer of Definium Therapeutics. "Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he's led the development of world-class commercial and operation

    1/29/26 7:00:00 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Financials

    Live finance-specific insights

    View All

    Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

    Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026 $411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028 Conference call scheduled today at 4:30 p.m. EST Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorder

    2/26/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care